Clinical Research Department

Mercer University

HIV Infections

Heart Failure

Immunologic Deficiency Syndromes

Renal Insufficiency

Iron-Deficiency Anemia

Acquired Immunodeficiency Syndrome

Sleep Apnea Syndromes

Iron Deficiencies

Respiratory Aspiration

Iron

E/C/F/TAF

Gilead Sciences

American Regent

CVRx

ResMed

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III, left ventricular ejection fraction (LVEF) ≤ 35% and NT-proBNP\<1600 pg/ml despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).

The total trial duration is anticipated to be approximately 5 years; however, the duration of an individual subject enrollment will depend on when he or she entered the trial.

Baroreflex Activation Therapy for Heart Failure

Mercer University | Clinical Research Department

Site insights

Work at this site?

Active trials

Baroreflex Activation Therapy for Heart Failure (BeAT-HF)

Trial sponsors